Workflow
AirSculpt Technologies(AIRS) - 2023 Q2 - Quarterly Report

PART I FINANCIAL INFORMATION This section covers the unaudited condensed consolidated financial statements and management's analysis Item 1. Financial Statements This section presents AirSculpt Technologies' unaudited condensed consolidated financial statements and related notes for the specified periods Condensed Consolidated Balance Sheets This section provides a snapshot of the company's financial position at specific dates, detailing assets, liabilities, and equity | Metric | June 30, 2023 ($000s) | December 31, 2022 ($000s) | Change ($000s) | Change (%) | | :-------------------------- | :----------------------- | :------------------------ | :-------------- | :--------- | | Cash and cash equivalents | 20,779 | 9,616 | 11,163 | 116.1% | | Total current assets | 26,829 | 16,676 | 10,153 | 60.9% | | Total assets | 217,284 | 200,759 | 16,525 | 8.2% | | Total current liabilities | 23,948 | 22,318 | 1,630 | 7.3% | | Total liabilities | 135,812 | 129,993 | 5,819 | 4.5% | | Total stockholders' equity | 81,472 | 70,766 | 10,706 | 15.1% | Condensed Consolidated Statements of Operations This section details the company's revenues, expenses, and net income or loss over specific reporting periods | Metric | 3 Months Ended June 30, 2023 ($000s) | 3 Months Ended June 30, 2022 ($000s) | Change ($000s) | Change (%) | 6 Months Ended June 30, 2023 ($000s) | 6 Months Ended June 30, 2022 ($000s) | Change ($000s) | Change (%) | | :---------------------------------- | :----------------------------------- | :----------------------------------- | :-------------- | :--------- | :----------------------------------- | :----------------------------------- | :-------------- | :--------- | | Revenue | 55,703 | 49,654 | 6,049 | 12.2% | 101,516 | 89,198 | 12,318 | 13.8% | | Total operating expenses | 50,341 | 45,691 | 4,650 | 10.2% | 94,392 | 86,406 | 7,986 | 9.2% | | Income from operations | 5,362 | 3,963 | 1,399 | 35.3% | 7,124 | 2,792 | 4,332 | 155.1% | | Net income/(loss) | 1,776 | 583 | 1,193 | 204.6% | 1,762 | (110) | 1,872 | N/A | | Basic EPS | 0.03 | 0.01 | 0.02 | 200.0% | 0.03 | (0.00) | 0.03 | N/A | | Diluted EPS | 0.03 | 0.01 | 0.02 | 200.0% | 0.03 | (0.00) | 0.03 | N/A | Condensed Consolidated Statements of Other Comprehensive Income/(Loss) This section presents net income alongside other comprehensive income or loss items not recognized in net income | Metric | 3 Months Ended June 30, 2023 ($000s) | 3 Months Ended June 30, 2022 ($000s) | 6 Months Ended June 30, 2023 ($000s) | 6 Months Ended June 30, 2022 ($000s) | | :------------------------------------ | :----------------------------------- | :----------------------------------- | :----------------------------------- | :----------------------------------- | | Net income/(loss) | 1,776 | 583 | 1,762 | (110) | | Change in foreign currency translation adjustment | (57) | — | (35) | — | | Comprehensive income/(loss) | 1,719 | 583 | 1,727 | (110) | Condensed Consolidated Statements of Changes in Stockholders' Equity This section outlines changes in the company's equity components, including common stock, additional paid-in capital, and accumulated deficit | Metric | June 30, 2023 ($000s) | December 31, 2022 ($000s) | Change ($000s) | Change (%) | | :-------------------------- | :----------------------- | :------------------------ | :-------------- | :--------- | | Common Stock (Amount) | 57 | 56 | 1 | 1.8% | | Additional Paid-in Capital | 94,836 | 85,858 | 8,978 | 10.5% | | Accumulated Deficit | (13,310) | (15,072) | 1,762 | -11.7% | | Total Stockholders' Equity | 81,472 | 70,766 | 10,706 | 15.1% | Condensed Consolidated Statements of Cash Flows This section reports cash inflows and outflows from operating, investing, and financing activities over specific periods | Metric | 6 Months Ended June 30, 2023 ($000s) | 6 Months Ended June 30, 2022 ($000s) | Change ($000s) | Change (%) | | :------------------------------------ | :----------------------------------- | :----------------------------------- | :-------------- | :--------- | | Net cash provided by operating activities | 18,455 | 17,478 | 977 | 5.6% | | Net cash used in investing activities | (5,976) | (6,139) | 163 | -2.7% | | Net cash used in financing activities | (1,316) | (1,433) | 117 | -8.2% | | Net increase in cash and cash equivalents | 11,163 | 9,906 | 1,257 | 12.7% | | Cash and cash equivalents, End of period | 20,779 | 35,253 | (14,474) | -41.1% | Notes to Condensed Consolidated Financial Statements (Unaudited) This section provides detailed explanations and additional information supporting the condensed consolidated financial statements NOTE 1 – ORGANIZATION AND SUMMARY OF KEY ACCOUNTING POLICIES This note details AirSculpt Technologies' organizational structure as a holding company, its practice management services, and key accounting policies - Company formed June 30, 2021, completed IPO on October 28, 2021, issuing 8,050,000 shares at $11.00 per share32 - AirSculpt is a holding company with 100% ownership in EBS Intermediate Parent LLC, concentrating revenues in the specialty, minimally invasive liposuction market3238 - Provides practice management services to professional associations (PAs) in the US, Canada, and UK, consolidating them as variable interest entities333436 - Revenue is recognized when patented AirSculpt® procedures are performed, with payment typically rendered in advance4042 - Cost of service includes compensation for doctors, nurses, clinical staff, supply costs, and facility rent43 NOTE 2 – GOODWILL AND INTANGIBLES, NET Goodwill remained constant at $81.7 million for both periods. Intangible assets, primarily technology and know-how, and trademarks, decreased slightly due to accumulated amortization - Goodwill remained at $81.7 million as of June 30, 2023, and December 31, 202259 | Metric | June 30, 2023 ($000s) | December 31, 2022 ($000s) | | :------------------------------------ | :----------------------- | :------------------------ | | Technology and know-how | 53,600 | 53,600 | | Trademarks and tradenames | 17,700 | 17,700 | | Accumulated amortization of technology and know-how | (16,973) | (15,186) | | Accumulated amortization of tradenames and trademarks | (5,605) | (5,015) | | Total intangible assets, net | 48,722 | 51,099 | - Aggregate amortization expense on intangible assets was approximately $1.2 million for both Q2 2023 and Q2 2022, and $2.4 million for both H1 2023 and H1 202260 NOTE 3 – PROPERTY AND EQUIPMENT, NET Net property and equipment increased to $28.9 million as of June 30, 2023, from $24.2 million at December 31, 2022, primarily due to investments in leasehold improvements and medical equipment | Metric | June 30, 2023 ($000s) | December 31, 2022 ($000s) | | :-------------------------- | :----------------------- | :------------------------ | | Medical equipment | 10,088 | 8,906 | | Leasehold improvements | 20,286 | 14,614 | | Property and equipment, net | 28,917 | 24,206 | - Depreciation expense was approximately $1.3 million for Q2 2023 (vs. $0.8 million in Q2 2022) and $2.5 million for H1 2023 (vs. $1.5 million in H1 2022)61 NOTE 4 – DEBT The company entered into a new credit agreement in November 2022, comprising an $85.0 million term loan and a $5.0 million revolving facility. Total debt, net, slightly decreased to $83.0 million as of June 30, 2023, and the company remains in compliance with all debt covenants - New credit agreement entered on November 7, 2022, maturing November 7, 2027, includes an $85.0 million term loan and a $5.0 million revolving loan facility62 | Metric | June 30, 2023 ($000s) | December 31, 2022 ($000s) | | :-------------------------- | :----------------------- | :------------------------ | | Term loan | 83,937 | 85,000 | | Unamortized debt discounts and issuance costs | (937) | (1,455) | | Total debt, net | 83,000 | 83,545 | | Long-term debt, net | 80,875 | 81,420 | - Interest rate as of June 30, 2023, was 7.23%63 - The company had $5.0 million available on the revolving credit facility and was in compliance with all covenants as of June 30, 20236465 NOTE 5 – LEASES The company's operating leases are primarily for real estate, including medical office suites and corporate offices. Operating cash outflows from leases and right-of-use assets increased, reflecting ongoing expansion and new lease obligations | Metric | 6 Months Ended June 30, 2023 ($000s) | 6 Months Ended June 30, 2022 ($000s) | | :------------------------------------ | :----------------------------------- | :----------------------------------- | | Operating cash outflows from operating leases | 2,544 | 2,026 | | Right-of-use assets obtained in exchange for lease obligations | 8,991 | 6,138 | - Rent expense for medical office suites was $1.4 million for Q2 2023 (vs. $1.0 million in Q2 2022) and $2.9 million for H1 2023 (vs. $2.0 million in H1 2022)66 | Year ended December 31, | Total Lease Payments ($000s) | | :------------------------------------ | :--------------------------- | | 2023 (excluding H1 2023) | 2,696 | | 2024 | 6,240 | | 2025 | 6,413 | | 2026 | 6,043 | | 2027 | 5,441 | | Thereafter | 12,273 | | Total lease obligations | 29,423 | NOTE 6 – STOCKHOLDERS' EQUITY AND EQUITY-BASED COMPENSATION The company granted both time-based restricted stock units (RSUs) and market-based performance stock units (PSUs) to executive officers and employees. Equity-based compensation expense decreased significantly for both the three and six months ended June 30, 2023, compared to the prior year - Granted 158,306 RSUs (Q2 2023) and 767,261 RSUs (H1 2023) with time-based vesting conditions70 - Granted 89,258 PSUs (Q2 2023) and 674,846 PSUs (H1 2023) with market-based vesting conditions (rTSR)71 | Metric | 3 Months Ended June 30, 2023 ($000s) | 3 Months Ended June 30, 2022 ($000s) | 6 Months Ended June 30, 2023 ($000s) | 6 Months Ended June 30, 2022 ($000s) | | :------------------------------------ | :----------------------------------- | :----------------------------------- | :----------------------------------- | :----------------------------------- | | Equity-based compensation expense | 4,603 | 7,316 | 8,991 | 14,591 | - Paid dividends of approximately $0.2 million for the six months ended June 30, 202373 NOTE 7 – EARNINGS PER SHARE Basic and diluted earnings per share significantly improved for both the three and six months ended June 30, 2023, reflecting the company's return to profitability. Potentially dilutive shares were excluded from calculations when their inclusion would be antidilutive | Metric | 3 Months Ended June 30, 2023 | 3 Months Ended June 30, 2022 | 6 Months Ended June 30, 2023 | 6 Months Ended June 30, 2022 | | :------------------------------------ | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Basic EPS | $0.03 | $0.01 | $0.03 | $(0.00) | | Diluted EPS | $0.03 | $0.01 | $0.03 | $(0.00) | | Weighted average shares outstanding - basic | 56,753,498 | 55,640,154 | 56,599,291 | 55,640,154 | | Weighted average shares outstanding - diluted | 58,511,766 | 58,360,685 | 58,095,736 | 55,640,154 | - Potentially dilutive shares (RSUs and PSUs) were excluded from diluted EPS calculation when antidilutive, particularly for the six months ended June 30, 2022, due to a net loss7677 NOTE 8 – INCOME TAXES The company reported income tax expense for both the three and six months ended June 30, 2023, with effective tax rates of 48.8% and 49.6%, respectively. The primary factor causing the difference between the effective and statutory rates is non-deductible executive compensation | Metric | 3 Months Ended June 30, 2023 ($000s) | 3 Months Ended June 30, 2022 ($000s) | 6 Months Ended June 30, 2023 ($000s) | 6 Months Ended June 30, 2022 ($000s) | | :------------------------------------ | :----------------------------------- | :----------------------------------- | :----------------------------------- | :----------------------------------- | | Income tax expense/(benefit) | 1,695 | 1,821 | 1,736 | (149) | | Effective tax rate | 48.8% | 75.7% | 49.6% | 57.5% | - The main driver of the difference between the effective and statutory tax rate is non-deductible executive compensation under Section 162(m) of the Internal Revenue Code78 - No uncertain tax positions were identified as of June 30, 2023, or December 31, 202278 NOTE 9 – COMMITMENTS AND CONTINGENCIES The company is routinely involved in legal actions, primarily medical malpractice claims, which are considered ordinary and not expected to have a material adverse effect on its financial condition. While liability insurance is maintained, there is no guarantee that coverage will be adequate for all future claims - Involved in pending and threatened legal actions, mostly medical malpractice claims, in the ordinary course of business79 - Believes the outcome of current legal actions will not have a material adverse effect on its business, financial condition, results of operations, and cash flows79 - Maintains liability insurance coverage, but cannot assure its adequacy for all future claims80 NOTE 10 – SEGMENT INFORMATION The company operates as a single reportable segment, 'direct medical procedure services,' which provides patented AirSculpt® procedures. The Chief Executive Officer, as the chief operating decision maker, reviews consolidated financial information, including revenue, gross profit, and Adjusted EBITDA, to assess performance and allocate resources - The company has one reportable segment: direct medical procedure services, offering patented AirSculpt® procedures81 - The Chief Operating Decision Maker (CODM), the CEO, reviews financial information on a consolidated basis, focusing on revenue, gross profit, and Adjusted EBITDA82 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section analyzes AirSculpt's financial condition and operational results, highlighting revenue growth, expense changes, and liquidity Overview This section provides a high-level summary of AirSculpt's business, its growth strategy, and key operational highlights - AirSculpt is a fast-growing national provider of minimally invasive body contouring procedures under the Elite Body Sculpture brand86 - Opened new centers in Orange County, CA (March 2023), Austin, TX (May 2023), London, UK (June 2023), and San Jose, CA (July 2023)86 - Operates 26 centers across 18 states, Canada, and the United Kingdom as of August 11, 202386 | Metric | 3 Months Ended June 30, 2023 | 3 Months Ended June 30, 2022 | Change (%) | 6 Months Ended June 30, 2023 | 6 Months Ended June 30, 2022 | Change (%) | | :-------------------------- | :--------------------------- | :--------------------------- | :--------- | :--------------------------- | :--------------------------- | :--------- | | Cases performed | 4,186 | 3,691 | 13.4% | 7,826 | 6,847 | 14.3% | | Revenue ($000s) | 55,703 | 49,654 | 12.2% | 101,516 | 89,198 | 13.8% | Key Operational and Business Metrics This section presents key performance indicators, including cases performed, revenue per case, and facility count, for overall and same-center operations | Metric | 3 Months Ended June 30, 2023 | 3 Months Ended June 30, 2022 | Change (%) | 6 Months Ended June 30, 2023 | 6 Months Ended June 30, 2022 | Change (%) | | :-------------------------- | :--------------------------- | :--------------------------- | :--------- | :--------------------------- | :--------------------------- | :--------- | | Cases | 4,186 | 3,691 | 13.4% | 7,826 | 6,847 | 14.3% | | Revenue per case | $13,307 | $13,453 | (1.1)% | $12,972 | $13,027 | (0.4)% | | Number of facilities | 25 | 19 | 31.6% | 25 | 19 | 31.6% | | Number of total procedure rooms | 53 | 38 | 39.5% | 53 | 38 | 39.5% | | Metric (Same-Center) | 3 Months Ended June 30, 2023 | 3 Months Ended June 30, 2022 | Change (%) | 6 Months Ended June 30, 2023 | 6 Months Ended June 30, 2022 | Change (%) | | :-------------------------- | :--------------------------- | :--------------------------- | :--------- | :--------------------------- | :--------------------------- | :--------- | | Cases | 3,589 | 3,691 | (2.8)% | 6,638 | 6,724 | (1.3)% | | Revenue per case | $13,249 | $13,452 | (1.5)% | $13,005 | $12,994 | 0.1% | | Number of facilities | 19 | 19 | 0.0% | 18 | 18 | 0.0% | | Number of total procedure rooms | 40 | 38 | 5.3% | 38 | 35 | 8.6% | Non-GAAP Financial Measures—Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income per Share This section defines and presents non-GAAP financial measures, including Adjusted EBITDA and Adjusted Net Income, providing insights into underlying business performance - Adjusted EBITDA is defined as net income/(loss) excluding depreciation and amortization, net interest expense, income tax expense/(benefit), restructuring and related severance costs, IPO related costs, (gain)/loss on disposal of long-lived assets, and equity-based compensation96 - Adjusted Net Income is defined as net income/(loss) excluding restructuring and related severance costs, IPO related costs, (gain)/loss on long-lived assets, equity-based compensation, and the tax effect of these adjustments97 | Metric | 3 Months Ended June 30, 2023 ($000s) | 3 Months Ended June 30, 2022 ($000s) | Change ($000s) | Change (%) | 6 Months Ended June 30, 2023 ($000s) | 6 Months Ended June 30, 2022 ($000s) | Change ($000s) | Change (%) | | :------------------------------------ | :----------------------------------- | :----------------------------------- | :-------------- | :--------- | :----------------------------------- | :----------------------------------- | :-------------- | :--------- | | Adjusted EBITDA | 14,612 | 13,977 | 635 | 4.5% | 24,068 | 22,919 | 1,149 | 5.0% | | Adjusted EBITDA Margin | 26.2% | 28.1% | (1.9)pp | -6.8% | 23.7% | 25.7% | (2.0)pp | -7.8% | | Adjusted Net Income | 7,643 | 8,158 | (515) | -6.3% | 12,528 | 15,169 | (2,641) | -17.4% | | Adjusted Net Income per Share (Basic) | $0.13 | $0.15 | $(0.02) | -13.3% | $0.22 | $0.27 | $(0.05) | -18.5% | | Adjusted Net Income per Share (Diluted) | $0.13 | $0.14 | $(0.01) | -7.1% | $0.22 | $0.26 | $(0.04) | -15.4% | - Pre-opening de novo and relocation costs were $1.4 million for Q2 2023 (vs. $1.2 million in Q2 2022) and $2.7 million for H1 2023 (vs. $2.1 million in H1 2022)100 Results of Operations This section provides a detailed comparative analysis of the company's financial performance for the current and prior reporting periods Three Months Ended June 30, 2023 Compared to Three Months Ended June 30, 2022 Revenue increased by 12.2% to $55.7 million, primarily driven by the addition of six de novo centers. Operating expenses also increased, but income from operations grew by 35.3%, and net income surged by 204.6% to $1.8 million | Metric | Q2 2023 ($000s) | Q2 2022 ($000s) | Change ($000s) | Change (%) | % of Revenue (Q2 2023) | % of Revenue (Q2 2022) | | :------------------------------------ | :-------------- | :-------------- | :-------------- | :--------- | :--------------------- | :--------------------- | | Revenue | 55,703 | 49,654 | 6,049 | 12.2% | 100.0% | 100.0% | | Cost of service | 19,952 | 17,492 | 2,460 | 14.1% | 35.8% | 35.2% | | Selling, general and administrative | 27,893 | 26,010 | 1,883 | 7.2% | 50.1% | 52.4% | | Depreciation and amortization | 2,514 | 1,962 | 552 | 28.1% | 4.5% | 4.0% | | Income from operations | 5,362 | 3,963 | 1,399 | 35.3% | 9.6% | 8.0% | | Net income | 1,776 | 583 | 1,193 | 204.6% | 3.2% | 1.2% | - Revenue increase is attributed to the addition of six de novo centers, expanding the footprint from 19 to 25 centers and procedure rooms from 38 to 53103 - Selling expenses increased by $1.8 million to $9.4 million, with customer acquisition costs rising from $2,000 to $2,250 per customer106 - Interest expense increased to $1.9 million from $1.6 million due to rising interest rates109 Six Months Ended June 30, 2023 Compared to Six Months Ended June 30, 2022 Revenue increased by 13.8% to $101.5 million, driven by the opening of six de novo centers. The company transitioned from a net loss of $0.1 million in H1 2022 to a net income of $1.8 million in H1 2023, despite increased cost of service and interest expenses | Metric | H1 2023 ($000s) | H1 2022 ($000s) | Change ($000s) | Change (%) | % of Revenue (H1 2023) | % of Revenue (H1 2022) | | :------------------------------------ | :-------------- | :-------------- | :-------------- | :--------- | :--------------------- | :--------------------- | | Revenue | 101,516 | 89,198 | 12,318 | 13.8% | 100.0% | 100.0% | | Cost of service | 37,969 | 32,154 | 5,815 | 18.1% | 37.4% | 36.0% | | Selling, general and administrative | 51,775 | 50,177 | 1,598 | 3.2% | 51.0% | 56.3% | | Depreciation and amortization | 4,850 | 3,848 | 1,002 | 26.0% | 4.8% | 4.3% | | Income from operations | 7,124 | 2,792 | 4,332 | 155.1% | 7.0% | 3.1% | | Net income/(loss) | 1,762 | (110) | 1,872 | N/A | 1.7% | (0.1)% | - Revenue per case decreased by 0.4% year-over-year, indicating that the overall revenue increase was volume-based112 - Cost of service as a percentage of revenue increased due to the addition of six de novo centers, which typically have higher costs in their initial years113 - Selling expenses increased to $18.0 million, with customer acquisition costs rising from $2,150 to $2,300 per customer116 - General and administrative expenses decreased primarily due to a reduction in equity-based compensation expense, despite an expansion of the corporate team117 - Interest expense increased to $3.6 million from $3.1 million due to rising interest rates119 Liquidity and Capital Resources This section discusses the company's ability to meet its short-term and long-term financial obligations, including cash flows and available credit - The company primarily relies on cash flows from operations and a $5.0 million revolving credit facility for liquidity121 - Cash and cash equivalents increased to $20.8 million as of June 30, 2023, from $9.6 million at December 31, 2022122 | Cash Flows Provided By (Used For) | 6 Months Ended June 30, 2023 ($000s) | 6 Months Ended June 30, 2022 ($000s) | | :------------------------------------ | :----------------------------------- | :----------------------------------- | | Operating activities | 18,455 | 17,478 | | Investing activities | (5,976) | (6,139) | | Financing activities | (1,316) | (1,433) | | Net increase in cash and cash equivalents | 11,163 | 9,906 | - Working capital improved significantly to $2.9 million at June 30, 2023, from a deficit of $(5.6) million at December 31, 2022124 - The carrying value of total indebtedness was $83.0 million as of June 30, 2023127 Item 3. Quantitative and Qualitative Disclosures About Market Risk As a smaller reporting company, AirSculpt Technologies, Inc. is exempt from providing detailed quantitative and qualitative disclosures about market risk - The company is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk134 Item 4. Controls and Procedures Management, including the Principal Executive Officer and Principal Financial Officer, concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2023. There were no material changes in internal control over financial reporting during the quarter - Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2023136 - No material changes in internal control over financial reporting occurred during the quarter ended June 30, 2023137 - Management acknowledges that any control system provides only reasonable, not absolute, assurance due to inherent limitations138 PART II OTHER INFORMATION This section includes disclosures on legal proceedings, risk factors, equity sales, defaults, and other miscellaneous information Item 1. Legal Proceedings The company is routinely involved in legal actions, primarily medical malpractice claims, which are considered ordinary and incidental to operations. These are not expected to have a material adverse effect on the company's financial condition, and insurance coverage is maintained, though its adequacy for all future liabilities is not guaranteed - The company is involved in pending and threatened legal actions, mostly medical malpractice claims, in the ordinary course of business141 - These legal actions are not expected to have a material adverse effect on the company's financial condition, results of operations, or cash flows141 - Liability insurance coverage is maintained, but there is no assurance that it will be adequate to cover all future claims141 Item 1A. Risk Factors There were no material changes to the risk factors previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2022, beyond any updates or additional factual information provided elsewhere in this Quarterly Report on Form 10-Q - No material changes to the risk factors discussed in the Annual Report on Form 10-K for the year ended December 31, 2022, except as updated in this 10-Q142 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds The company reported no unregistered sales of equity securities or use of proceeds for the period - No unregistered sales of equity securities and use of proceeds to report143 Item 3. Defaults Upon Senior Securities The company reported no defaults upon senior securities for the period - No defaults upon senior securities to report144 Item 4. Mine Safety Disclosures This item is not applicable to the company's operations - Mine Safety Disclosures are not applicable to the registrant145 Item 5. Other Information The company reported no other information for the period - No other information to report146 Item 6. Exhibits This section lists all exhibits filed as part of the Form 10-Q, including certifications from principal officers, the Amended and Restated Certificate of Incorporation, and various Inline XBRL taxonomy documents - Includes certifications of Principal Executive Officer and Principal Financial Officer (Exhibits 31.1, 31.2, 32.1, 32.2)148 - Includes the Amended and Restated Certificate of Incorporation (Exhibit 3.1)148 - Includes various Inline XBRL taxonomy extension documents (Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, 101.PRE, 104)148 Signatures The Quarterly Report on Form 10-Q was duly signed on behalf of AirSculpt Technologies, Inc. by Dennis Dean, Chief Financial Officer, on August 11, 2023 - The report was signed by Dennis Dean, Chief Financial Officer, on August 11, 2023154